Trial results

$DYN — z-basivarsen (DYNE-101)

Dyne Therapeutics, Inc. (DYN) z-basivarsen (DYNE-101): trial results in Myotonic dystrophy type 1 (DM1), 2027.

Research by Catalyst Intel

The catalyst

"Dyne continues to expect topline data in Q1 2027 from the ACHIEVE registrational expansion cohort (REC), with a primary endpoint of change from baseline in vHOT at 6 months, intended to support a potential submission for U.S. Accelerated Approval in Q3 2027"

— Dyne Therapeutics, 8-K filed 2026-09-29 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

DYN-ZBASIVARSEND-2026

Company

Dyne Therapeutics, Inc.

Kind

Trial results

Indication

Myotonic dystrophy type 1 (DM1)

Window

2027-01-01 – 2027-03-31

Status

slate

The bar

No bar has been published for this event yet.

Verdicts

Sealed with the bar. Any verdict for this event reaches this page on 2027-04-30; subscribers get it on the day.